Breast Cancer Updates for Pharmacists
FDA Approves Abemaciclib, Endocrine Therapy for Early Breast Cancer
November 3, 2021
The FDA approved the combination of abemaciclib and either tamoxifen or an aromatase inhibitor for adjuvant treatment for some adults with HR-positive HER2-negative, node-positive, early breast cancer...
Women with Breast Cancer at Increased Risk for Developing Atrial Fibrillation
December 13, 2021Women with breast cancer have an increased risk for developing atrial fibrillation (AF) in the first year after diagnosis...
FDA Approved Cancer Drugs Are Still Getting Prescribed Even When Lacking Clinical Benefit In Trials
October 6, 2021Cancer drugs that receive accelerated approval from the FDA, but fail to show improvement in the primary endpoint are still being prescribed and included in clinical treatment guidelines...
Manufacturer Withdraws Atezolizumab from FDA Accelerated Approval for Triple-negative Breast Cancer
September 9, 2021Genentech has voluntarily withdrawn the accelerated approval of atezolizumab (Tecentriq) combined with albumin-bound paclitaxel as a first-line treatment for patients with locally advanced or metastatic PD-L1-positive, triple-negative breast cancer...
Genetic Test Predicts Toxicity Among Breast Cancer Patients Undergoing Radiotherapy Treatment
August 10, 2021For individuals with breast cancer, the potential for toxicity after radiotherapy is a real concern. Yet as a multi-center team of Italian researchers recently found...
Study Identifies, Quantifies Rare Histological Subtypes of Triple Negative Breast Cancer
July 9, 2021One of the largest studies of its kind has suggested that histological type may be associated with a host of outcomes in breast cancer, – including overall survival, treatment response, and clinical course – despite ...
